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Lung cancer is still the leading cause of morbidity and 
death all over the world, representing the 17% of new 
diagnoses in men and the 23% of total cancer mortality (1). 
Non-small-cell lung cancer (NSCLC) accounts for about 
85% of lung cancers with most of the patients presenting 
advanced disease at the time of diagnosis, and with a 5-year 
survival less than 5% (2). Standard therapy, such as systemic 
chemotherapy, has reached a plateau in effectiveness and 
causes significant toxicity to the patients (3). However, 
enhanced understanding of cellular and molecular 
mechanisms of tumor progression has allowed for the 
discovery of specific molecular targets and the development 
of targeted therapies. At this regard, the standard first-line 
treatment for NSCLC patients that present mutations in the 
EGFR is now the use of EGFR inhibitors (4). Despite these 
improvements, prognosis remains poor, and alternative 
strategies for this devastating disease are required. 
It has long been established that angiogenesis is a 
rate-limiting step during tumor growth (5). The VEGF 
ligands and their cognate receptors constitute the most 
essential axis of signaling for blood vessel formation in 
tumor angiogenesis (6). Current strategies based on the 
combination of small tyrosine kinase inhibitors acting 
on VEGF ligands or VEGF receptors with cytotoxic 
agents have been exploited in cancer patients including 
those with advanced-stage NSCLC (2). However, tumors 
that may be initially responsive to available treatments 
can acquire resistance (2). Redundant angiogenic factors 
with up-regulation of alternative angiogenic signals, 
induction of hypoxia, selection of more aggressive tumor 
cells, recruitment of bone-marrow-derived myeloid cells 
that favor angiogenesis, modification of vascular pericyte 
coverage and vessel cooption are the main mechanisms 
through which resistance takes place (6).
The limited success of molecularly targeted therapies 
either alone or in combination has spurred the development 
of alternative approaches (7). Nowadays, based on 
their antiangiogenic potential, other agents, different 
from those interfering with the VEGF axis, are under 
clinical development (8). In this context, genetic and 
pharmacological studies uncovered a critical role for the 
Notch cell-to-cell signaling family of transmembrane 
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receptors and ligands, not only in vessel biology (9,10), 
but also in tumor angiogenesis (8). Endothelial cells (ECs) 
express several Notch receptors (Notch1, 4) and ligands 
(Delta-like 1, 4 and Jagged1). Among these, Notch1 and 
Delta-like 4 (Dll4) are recognized as key players (9). 
The haploinsufficiency of VEGF and Dll4 ligands is a proof 
of concept of the crucial role played by the bioavailability 
of VEGF and Dll4 during vessel patterning (11). During 
angiogenesis, in response to VEGF, vascular cells degrade 
the surrounding extracellular matrix, proliferate, and migrate 
to form new blood vessels (10). Vascular sprouting results 
from the ability of this potent angiogenic factor to increase 
the expression of membrane-bound Dll4 on specialized ECs, 
denoted as “tip cells” (9,10,12). As the result of the Dll4 
expression and the activation of the Dll4/Notch1 signaling 
on adjacent ECs the “stalk cell” phenotype is induced, the 
tip cell behavior is restrained and vascular sprout towards the 
angiogenic cue limited. Therefore, as elegantly demonstrated 
by Hellström et al. (13), Dll4/Notch1 signaling is required for 
an appropriate ratio between tip and stalk cells leading to a 
proper branching formation in response to VEGF.
Moreover, a number of studies strongly support a picture 
in which Dll4-Notch signaling serves as a negative regulator 
of VEGF-induced angiogenesis. This implies that VEGF 
acts as a central driver of angiogenesis, while Dll4/Notch 
signaling helps to coordinate the response appropriately 
(10,14,15).
In analogy with developmental process, in experimental 
tumor models the principle of tip-stalk specification by 
Notch signaling seems to be crucial in tumor angiogenesis. 
Therefore based on the crucial role of Dll4/Notch signaling 
in the selection of tip cells and vascular sprouting, a number 
of therapeutic approaches targeting this pathway have 
been proposed (16). Noguera-Troise et al. (17), elegantly 
demonstrated that blockade of Dll4 signaling, either by 
using selective anti-Dll4 antibody or an Fc-Dll4 fusion 
protein, led to an increased number of tip cells and an hyper-
dense immature vascular network in C6 glioma tumor-
bearing mice. Unexpectedly Dll4 blockade leads to the so 
called “non-functional angiogenesis”, resulting in a striking 
uncoupling of tumor growth from vessel density. Consistent 
with these data, immunotherapeutic approaches, targeting 
Dll4 by DNA vaccination significantly attenuated the 
growth of orthotopically implanted ERBB2+ mammary 
carcinomas in mice by induction of a disproportionate 
and poorly perfused vascular bed (18). Overall these data 
indicate that interference with the Dll4/Notch signaling led 
to an aberrant vascular patterning unable to support tumor 
growth. However, continuous dosing with anti-Dll4 mAb has 
resulted in new vessel formation and angiomas in different 
experimental models (19). Thereby, it has been suggested 
that a more efficacious anti-angiogenesis therapy could be 
obtained by simultaneously targeting VEGF and Dll4 (20).
Nevertheless, the significant pathophysiology of Notch 
signaling pathway in tumors have spurred clinicians to 
move from preclinical to the clinical trial by exploiting 
agents that either hinder Notch receptor cleavages such as 
gamma-secretase inhibitors (GSIs), or interfere with the 
Notch ligand-receptor interaction, including humanized 
monoclonal antibodies (mAbs). Although antitumor activity 
by GSIs and mAbs administered as single agent in early 
phases of clinical trials has been observed in different 
advanced or metastatic cancers, a number of mechanism-
based adverse events, particularly gastrointestinal toxicities, 
emerged (21). To mitigate treatment-related toxicities of 
such molecularly targeted therapies, alternative approaches 
based on dose and schedule drug delivery with tolerable 
safety profile are nowadays under investigation (8).
Despite these advancements in many types of solid tumors, 
the role of Notch1 signaling in lung tumors is still debated 
(21,22). Notch1 and Notch2 are frequently expressed in 
NSCLCs and have been suspected to have a growth promotion 
function (22). However, recent studies demonstrated a 
reduced or even undetectable Notch1 expression in NSCLC. 
This implies a putative Notch1 tumor-suppressive role in 
these tumors (23,24) and suggests that Notch function in 
NSCLC is more complex than expected. At this regard 
apparently discordant effects of over-expressing Notch1 have 
been reported in a well known model of NSCLC, the A549 
cell line. These cells can undergo cell death when Notch1 
over-expression was obtained by in vitro manipulation but 
can  activate cell survival signals when cultured in hypoxic 
conditions that mimic tumor microenvironment (23). 
Although discordant, these observations simply reflect the 
biological pleiotropy of Notch in developmental processes 
where Notch signaling outcome basically depends on the 
specific tissue context, microenvironment and cross-talk with 
other signaling pathways (21). 
As described above, Notch acts as a juxtacrine signaling 
molecule. Indeed, Notch signaling is initiated by binding of 
a Notch ligand expressed on one cell to a Notch receptor on 
a neighboring cell (9). Based on this notion, Ding et al. (25) 
have proposed an alternative strategy to impair NSCLC 
tumor growth. They hypothesized that the cross-talk 
between ECs and A549 tumor cells might mimic tip-stalk 
cell interaction, restraining tumor cell growth. Interestingly, 
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they showed that ECs over-expressing Dll4, when 
co-cultured with A549 cells, can suppress tumor cell in vitro 
and in vivo proliferation, leading to a marked decrease in 
the in vivo tumor growth. Unexpectedly, instead of inducing 
non-functional angiogenesis, Dll4 silencing on ECs was 
associated with enhanced NSCLC cell proliferation and 
in vivo tumor formation. Moreover, although they did 
not discriminate between A549 and ECs, they showed 
that Notch1 and its nuclear targets are up-regulated in 
tumor cells when co-cultured with Dll4 expressing ECs. 
To sustain the inhibitory pathway, Ding et al. (25), also 
showed a correlation between expression of Notch1 and 
the oncosuppressive protein PTEN in xenografts derived 
from tumor cells co-injected with Dll4 expressing ECs. 
They did not prove formally that PTEN is transcriptionally 
regulated by Notch1, however these data are in line with 
the observation that PTEN is a direct Notch1 target in 
prostate adenocarcinoma cells (26). 
It is well known that transcriptional activation of 
Notch target genes includes either genes involved in cell 
proliferation/survival and genes related to growth arrest (8). 
This implies that the outcome of Notch activation widely 
differs with cellular context and dose, from apoptosis to 
cell survival, and unrestrained growth to growth arrest. 
The data by Ding et al. (25), although provocative in 
providing a novel and alternative strategy targeting Notch 
pathway in NSCLCs, once again might recapitulate the 
pleiotropy of the Notch1 signaling in tumor cell biology. 
This suggests that to clarify the mechanisms underpinning 
Notch1 expression/activation in lung cancer further studies 
are requested. Moreover, the relevance of Dll4/Notch1 
signaling in driving tumor growth inhibition, provided by 
this study, suggests that particular attention may be devoted 
to understand the mechanisms regulating stroma/tumor 
cell direct interaction as well. If validated, these data would 
provide the rational basis to future efforts in developing 
novel druggable targets to specifically hinder lung tumor 
growth. Finally, in light of these data, an additional 
challenge would be to identify a lung cancer preclinical 
model that reliably quantify the effects of Dll4/Notch1 in 
both tumor and stroma cells. Such a model would predict 
the growth inhibitory potential mediated by high levels of 
Notch1 expression and eventually, it would be useful to 
identify patients eligible for this therapeutic approach. 
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